Changing Geographic Distribution of Japanese Encephalitis Virus Genotypes, 1935-2017.


Journal

Vector borne and zoonotic diseases (Larchmont, N.Y.)
ISSN: 1557-7759
Titre abrégé: Vector Borne Zoonotic Dis
Pays: United States
ID NLM: 100965525

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 13 9 2018
medline: 10 4 2019
entrez: 13 9 2018
Statut: ppublish

Résumé

Japanese encephalitis virus (JEV) is a representative virus of the JEV serogroup in genus Flavivirus, family Flaviviridae. JEV is a mosquito-borne virus that causes Japanese encephalitis (JE), one of the most severe viral encephalitis diseases in the world. JEV is divided into five genotypes (G1-G5), and each genotype has its own distribution pattern. However, the distribution of different JEV genotypes has changed markedly in recent years. JEV G1 has replaced G3 as the dominant genotype in the traditional epidemic areas in Asia, while G3 has spread from Asia to Europe and Africa and caused domestic JE cases in Africa. G2 and G5, which were endemic in Malaysia, exhibited great geographical changes as well. G2 migrated southward and led to prevalence of JE in Australia, while G5 emerged in China and South Korea after decades of silence. Along with these changes, JE occurred in some non-traditional epidemic regions as an emerging infectious disease. The regional changes in JEV pose a great threat to human health, leading to huge disease burdens. Therefore, it is of great importance to strengthen the monitoring of JEV as well as virus genotypes, especially in non-traditional epidemic areas.

Identifiants

pubmed: 30207876
doi: 10.1089/vbz.2018.2291
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-44

Auteurs

Xiaoyan Gao (X)

1 Department of Science and Technology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Hong Liu (H)

4 Shandong Provincial Research Center for Bioinformatic Engineering and Technique, School of Life Sciences, Shandong University of Technology, Zibo, China.

Xiaolong Li (X)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Shihong Fu (S)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Lei Cao (L)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Nan Shao (N)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Weijia Zhang (W)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Qianying Wang (Q)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Zhi Lu (Z)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Wenwen Lei (W)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Ying He (Y)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Yuxi Cao (Y)

1 Department of Science and Technology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Huanyu Wang (H)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Guodong Liang (G)

2 State Key Laboratory of Infectious Disease Prevention and Control, Department of Viral Encephalitis and Arbovirus, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH